Non-alcoholic fatty liver disease (NAFLD) in the Western Cape : a descriptive analysis by Kruger, F. C. et al.
168
Non-alcoholic fatty liver disease (NAFLD) is a complex 
disorder characterised by histological abnormalities identified 
on liver biopsy in patients who consume little or no alcohol 
but present with histological features similar to those seen in 
alcoholic liver disease. NAFLD is the most prevalent chronic 
liver disease in Western countries. In the USA the estimated 
prevalence is 17 - 33%.1 
Non-alcoholic steatohepatitis (NASH) is a subset of NAFLD. 
The estimated prevalence of NASH in the USA is  
6 - 17%.1 NASH is not a benign liver disease – it  may result 
in increased rates of cirrhosis, hepatocellular carcinoma, 
liver transplantation and death.2 NASH increases in parallel 
with increases in obesity and sedentary lifestyle.3 The risk of 
developing cirrhosis from NASH is approximately 20% over 10 
years. The National Institute of Health (NIH) in the USA found 
the highest rates of obesity among the least educated with 
the highest poverty rates.4 This finding may be of relevance 
to the South African population, as the overall prevalence of 
overweight (body mass index (BMI) >25) and obesity (BMI 
>30) in South Africa is very high, with more than 29% of men 
and 56% of women being classified as overweight or obese.5 
The major risk factors for advanced NAFLD include age 
(>45 - 50 years), overweight/obesity, insulin resistance (even in 
young, non-obese individuals) and ethnicity.6 The prevalence 
of NAFLD/NASH in African Americans appears to be lower 
than that for other population groups in the USA, despite 
their over-representation of the major risk factors.7,8 Ethnicity 
as a major risk factor for NASH has also been highlighted by 
a postmortem paediatric study in the USA showing that there 
are distinct histopathological differences in NAFLD/NASH 
between Caucasians and the minority race groups.9 African 
Americans were also poorly represented in this study, again 
highlighting their low prevalence of NAFLD/NASH.
Ethnic differences suggest a role for genetic factors in 
susceptibility to developing advanced NAFLD, which is 
supported by family studies. Numerous candidate genes 
involved in the development and progression of this condition 
have been investigated.10,11 
We aimed to describe the clinical characteristics, 
demographics and biochemical features in South African 
patients in the Western Cape screened for and diagnosed with 
NAFLD/NASH. 
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Background. Non-alcoholic fatty liver disease (NAFLD) is the 
most prevalent chronic liver disease in Western countries, but 
the disease profile has not yet been described in South Africa. 
NAFLD affects all spheres of society, especially the poorest 
and least educated.
Aim. To investigate the demographics and clinical and 
biochemical features of South African patients diagnosed with 
non-alcoholic fatty liver and non-alcoholic steatohepatitis 
(NASH) in the Western Cape, South Africa.
Design/method. Overweight/obese subjects were screened by 
ultrasound and those with fatty liver/hepatomegaly were 
included. Liver biochemistry, insulin resistance (using the 
insulin resistance homeostasis model assessment method for 
insulin resistance, HOMA-IR) and body mass index were 
assessed and liver biopsies were performed on patients older 
than 45 years with persistently abnormal liver function and/
or hepatomegaly.
Results. We screened 233 patients: 69% coloured, 25% 
Caucasian, 5% black and 1% Asian. The majority (73%) were 
female. NAFLD was confirmed histologically in 111 patients, 
of whom 36% had NASH and 17% advanced liver fibrosis. 
No black patient had advanced fibrosis. Subjects with NASH 
had higher mean triglyceride (p=0.03) and cholesterol (p=0.01) 
levels than subjects with NAFL. All patients were insulin 
resistant/diabetic. HOMA-IR and not the degree of obesity 
was strongly associated with advanced fibrosis (p=0.09).
Conclusion. This study is the first to describe the clinical 
characteristics of NAFLD in South Africa, albeit only in the 
Western Cape population. Insulin resistance was the universal 
factor present. The degree of obesity was not associated with 
severity of disease. The role of genetic risk factors in disease 
development and severity remains to be defined.
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Subjects and methods
The study protocol was approved by the Ethics Review 
Committee of Stellenbosch University, and all patients included 
signed informed consent.
We included patients who attended the clinics at the 
Gastroenterology and Hepatology Unit of the Division of 
Internal Medicine at Tygerberg Hospital and Louis Leipoldt 
and Durbanville Medi-Clinics. Between July 2003 and 
December 2006, 233 overweight/obese patients with features 
suggestive of the metabolic syndrome were screened for 
hepatic steatosis by ultrasonography. 
Study design
The following aspects were investigated: gender, age, ethnicity, 
total cholesterol and triglyceride levels, type 2 diabetes 
mellitus (DM2), insulin resistance (using the insulin resistance 
homeostasis model assessment method for insulin resistance, 
HOMA-IR) and BMI. Known diabetics were excluded from 
HOMA-IR calculations.
Subjects were grouped according to those who fulfilled the 
criteria for NASH and NAFL. NAFL is defined as steatosis only 
or steatosis with inflammation but not fulfilling the criteria 
for NASH. The subjects with histological features suggestive 
of another liver disease were excluded. Subjects were also 
grouped according to the severity of fibrosis: advanced 
fibrosis (grade 3 and 4) or no/mild fibrosis (grade 0, 1 and 2), 
according to Kleiner et al.12 
Biochemical parameters 
Liver function, serum glucose, serum insulin and lipograms 
were determined after an overnight fast, using standard 
laboratory techniques. Additional blood tests were performed 
where necessary to exclude other liver diseases. HOMA-IR was 
calculated as follows: fasting glucose × fasting insulin/22.5.
Anthropometric parameters
Height and weight measurements were recorded from which 
BMIs were calculated as follows: mass in kg/ length in m2. 
Liver biopsies
Liver biopsies were performed percutaneously under 
ultrasound guidance, or laparoscopically during 
cholecystectomy for patients with ultrasonographic evidence of 
steatosis, on patients older than 45 years with fatty infiltration 
on ultrasound and/or who had persistently abnormal liver 
function and/or hepatomegaly. 
Histological analysis
Liver biopsies were reviewed by the same two pathologists 
using the criteria of the NIH Non Alcoholic Steatohepatitis 
Clinical Research Network (NIH NASH CRN).12
Statistical analysis
For descriptive purposes, cross-tabulation and frequency tables 
were used to describe occurrences of various attributes (e.g. 
gender, ethnicity, etc.) of the sample. Comparisons between 
different groupings of the sample for measurements (e.g. BMI, 
HOMA-IR, etc.) were done using one-way analysis of variance 
(ANOVA). A 5% significance level was used as guideline for 
determining significant differences. 
Results
The subjects screened were ethnically classified as  coloured 
(69%),  Caucasian (25%),  black (5%) and  Asian (1%). The 
majority (73%) of the patients were female.
A total of 182 patients (87%) had ultrasonographic evidence 
of fatty infiltration and/or hepatomegaly. Of the group with 
an ultrasound scan suggesting fatty liver and who fulfilled the 
criteria for liver biopsy, 127 consented to biopsy. NAFLD was 
confirmed in 111 (87%), and of those with NAFLD 46 (36%) 
had NASH. Fig. 1a displays histological findings of the group 
that underwent liver biopsy. Sixty-three (54%) of the patients 
had no histological evidence of fibrosis, while 20 (17%) had 
advanced liver fibrosis (stages 3 - 4) (Fig. 1b). Fig. 2 illustrates 
the difference between the males and females affected by 
NAFLD with reference to NASH versus NAFL and advanced 
fibrosis versus no/mild fibrosis.
Fig. 3 illustrates the association between patient age and 
presentation with NAFL/NASH as well as no/mild fibrosis 
and advanced fibrosis. The mean age for the group with fatty 
liver disease was 50 years (range 48 - 53 years) versus 54 
years (51 - 58 years) for NASH (p=0.1). The mean ages of the 
groups with fatty liver disease and NASH were 50 years (95% 
confidence interval (CI) 48 - 53 years) and 54 years (95% CI 
51 - 58 years) (p=0.1), The mean for the group with no or mild 
fibrosis was 51 years (95% CI 49 - 53 years) and that for the 
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Fig. 1a.  Histological staging based on NIH NASH CRN.
Fig. 1b. Fibrosis grading based in NIH NASH CRN.
 
Fig. 1b. ibrosis grading based in 
 
 
 






NIH NASH CRN. 



 
March 2010, Vol. 100, No. 3  SAMJ
170
group with advanced fibrosis 57 years (95% CI 49 - 65 years) 
(p=0.06).
Fig. 4 illustrates the differences between the ethnic groups 
with regard to presentation with NASH versus NAFL and 
grading of fibrosis. The Asian population group was excluded 
from the figure, since there was only 1 patient in this group.
Fig. 5 illustrates the prevalence of DM2 in the different 
groups.
Table I displays the mean total cholesterol level (mg/dl), 
serum triglyceride level (mg/dl), BMI (kg/m2) and HOMA-IR 
for each group.
Discussion 
We describe the disease profile of NAFLD/NASH for the 
first time in South African patients in the Western Cape 
region. Their clinical characteristics are described in terms 
of histological features and presence of fibrosis, in relation 
to gender, age, ethnicity, DM2, HOMA-IR and BMI. Our 
findings are similar to observations elsewhere in the world.13,14 
However, the majority (73%) of our patients were female. 
Gender was not associated with severity of NAFLD in this 
cohort of patients.
Patients were required be 45 years and older to receive 
a liver biopsy. Although older age was not associated with 
NASH, it was associated with more advanced fibrosis. 
Ethnicity independently was shown to be an important risk 
factor for advanced disease in the USA.7,8 African American 
subjects appear to be protected against advanced disease.8 
Our findings suggest the same, despite black patients being 
under-represented. This warrants further studies to draw 
comparisons with US studies. 
Insulin resistance is the common pathogenic factor in the 
majority of patients with NAFLD when other causes have 
been excluded.13 The subjects not diagnosed with DM2 had 
a markedly increased mean HOMA-IR. This confirms the 
pathogenic role of insulin resistance in subjects with NAFLD. 
Even though insulin resistance was not predictive of NASH 
there was a strong tendency towards predicting advanced 
fibrosis. DM2 is an independent risk factor for more advanced 
disease, but our study was unable to demonstrate this.14
Fig. 2. Gender and association with NAFLD.
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Table I. Biochemical and anthropometric parameters 
      NAFL      95% CI       NASH      95% CI       p-value      No/mild fibrosis     95% CI     Advanced fibrosis      95% CI     p-value
Total         5.4      5.1 - 5.8         6.1         5.7 - 6.5        ≤0.01                   5.7             5.4 - 6.0               5.8               5.1 - 6.4  0.95
cholesterol
(mg/dl)
Triglycerides  1.9      1.3 - 2.6         3.1         2.3 - 3.9        0.03        2.3             1.2 - 2.9        2.9               1.7 - 4.2  0.38
(mmol/l)
BMI       36      34 - 38           34         32 - 36          0.17        36             34 - 37        31                28 - 34  0.01
(kg/m2)
HOMA-IR     5.7      2.8 - 8.6         6.1         4.3 - 8           0.8        5.8             3.5 - 8.1        11                5.3 - 16.7  0.09
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 4. Ethnicity and association with NAFLD. 
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Fig. 5. Diabetes mellitus and association with NAFLD.
 
 
 
 
 
 
 
Fig. 3. Age and association with NAFL.
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There was a statistically significantly difference in the mean 
serum triglycerides and total cholesterol levels in subjects with 
NAFL and NASH, but not for subjects with no/mild fibrosis 
compared with advanced fibrosis. These findings implicate 
dyslipidaemia but not advanced fibrosis in the development of 
NASH. 
Even though all our patients were either overweight or 
obese, the presence of more marked obesity did not predict the 
presence of more advanced disease. Our findings suggest that 
obesity, insulin resistance and dyslipidaemia are important 
factors in the development of NAFL and NASH, while 
secondary factors involving gene-environment interactions 
may be required to develop advanced fibrosis.15
In conclusion, we present the first clinical description of 
NAFLD in a South African setting, with particular emphasis 
on the unique coloured population of the Western Cape. Their 
phenotype was more similar to that of the Caucasians than the 
black population group. Insulin resistance was the key factor, 
present in all the patients. Further studies are warranted to 
identify the role of genetic risk factors in the development of 
NAFLD and progression to advanced disease. 
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